$241 Million is the total value of Artia Global Partners LP's 27 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVO | Buy | NOVO-NORDISK A Sadr | $62,003,983 | +12.4% | 681,812 | +100.0% | 25.78% | +35.5% |
| ARGX | Buy | ARGENX SEsponsored adr | $24,206,878 | +33.8% | 49,238 | +6.0% | 10.06% | +61.3% |
| LLY | Buy | LILLY ELI & CO | $14,069,046 | +85.3% | 26,193 | +61.8% | 5.85% | +123.4% |
| Buy | ROIVANT SCIENCES LTD | $10,675,789 | +28.5% | 914,023 | +10.9% | 4.44% | +55.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NOVO-NORDISK A S | 4 | Q3 2023 | 25.8% |
| MERCK & CO INC | 4 | Q3 2023 | 14.1% |
| ARGENX SE | 4 | Q3 2023 | 12.3% |
| LILLY ELI & CO | 4 | Q3 2023 | 14.5% |
| ABBVIE INC | 4 | Q3 2023 | 5.6% |
| ASTRAZENECA PLC | 4 | Q3 2023 | 5.4% |
| SEAGEN INC | 4 | Q3 2023 | 4.5% |
| BIOMARIN PHARMACEUTICAL INC | 4 | Q3 2023 | 4.3% |
| NEUROCRINE BIOSCIENCES INC | 4 | Q3 2023 | 2.1% |
| VERTEX PHARMACEUTICALS INC | 4 | Q3 2023 | 2.6% |
View Artia Global Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
View Artia Global Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.